Without a fresh headline to point to, Haemonetics (HAE) is still drawing attention after a strong past 3 months and year. Investors are weighing recent share performance against fundamentals and valuation.
At a share price of US$101.06, Haemonetics has slipped over the past week but still carries a 30-day share price return of 15.87% and a 90-day move of 29.23%. The 1-year total shareholder return of 88.97% signals strong positive momentum that investors are now weighing against the current valuation.
Extend your research beyond Haemonetics by checking a hand picked 33 high quality undervalued stocks that combines strong fundamentals with more modest valuations.
Haemonetics has already rewarded shareholders sharply over the past year, so fresh buyers now face a simple fork in the road: pay up at today’s price, or wait and risk missing further rerating as the valuation case unfolds.
Most Popular Narrative: 6.8% Undervalued
On the most followed view of Haemonetics, a fair value of $108.40 sits modestly above the last close at $101.06, which frames the current debate around upside.
Enterprise-wide portfolio transformation, highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions, is driving substantial gross and operating margin expansion (guidance of 26–27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.
Want to see how Haemonetics gets from today’s earnings base to that higher fair value? The narrative leans heavily on faster profit growth, wider margins, and a richer future earnings multiple that together carry most of the valuation weight.
Result: Fair Value of $108.40 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the Haemonetics story could look very different if CSL volumes disappoint or if VASCADE underperformance drags on longer than analysts currently model.
Find out about the key risks to this Haemonetics narrative.
Next Steps
Mixed signals around Haemonetics can create pressure to react quickly, so consider acting sooner rather than later and carefully weigh both 2 key rewards and 3 important warning signs.
Looking for more ideas beyond Haemonetics?
Do not stop at Haemonetics. Use the Simply Wall Street Screener to surface fresh opportunities that fit your return goals and risk comfort.
- Target steadier portfolio behaviour by hunting for companies that show resilient fundamentals in the 11 resilient stocks with low risk scores.
- Spot potential value candidates early by scanning a curated 33 high quality undervalued stocks before other investors turn their attention there.
- Uncover overlooked potential by reviewing a 18 high quality undiscovered gems that many portfolios may not yet own.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com